Company intelligence / Profile preview

Virtech Industries

Natick, Massachusetts, United Statesau.linkedin.com ↗

Overview

VirTech Bio has developed OxyBridge™, a next-generation hemoglobin-based oxygen carrier designed to address FDA toxicity concerns and improve safety. The lead program targets pre-transplant organ perfusion as an ex vivo device, with lower regulatory hurdles. The company has received $13.7M in non-dilutive funding from the US Army Medical Research and Development Command (USAMRDC) via MTEC and US Special Operations Command (SOCOM), supporting R&D, eGMP manufacturing, and a planned Phase I clinical study[3][10].

2 assets

Pre-clinical

1 more asset in the full pipeline.

Beyond the preview

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Follow clinical development from trial design and recruitment through results.

Explore licensing agreements, acquisitions, and the assets behind each deal.

Trace financing activity and the investors behind a company’s development.

Compare peer pipelines by target, modality, and therapeutic area.

Explore technology platforms and the patent landscape around relevant assets.

Connect company news and source material to the questions you’re investigating.

See how Gosset can support your research on Virtech Industries.